

Supplementary Material

Constructing and validating a Nomogram model for short-term prognosis of patients with AChR-Ab+ GMG

Feng Liang^{1,2}, Zhaoxu Yin³, Yaqian Li^{1,2}, Guanxi Li^{1,2}, Jing Ma^{1,2}, Huiqiu Zhang^{1,2}, Xiaoqian Xia², Make Yao⁴, Xiaomin Pang¹, Juan Wang¹, Xueli Chang¹, Junhong Guo¹, Wei Zhang^{1#}

1Department of Neurology, the First Hospital of Shanxi Medical University, Taiyuan, China

2First Clinical Medical College, Shanxi Medical University, Taiyuan, China

3 Taiyuan City Central Hospital, Department of Neurology, Taiyuan, China

4 Shanxi Medical University, Taiyuan, China

#Correspondence to:

Wei Zhang

Institute: Department of Neurology, First Hospital, Shanxi Medical University,
Address: No.85, Jiefang South Street, Taiyuan, China

E-mail: zhangvey@126.com;

Supplementary Table1 Overview of the included study indicators

Characteristics	Poor efficacy	Good efficacy	P value
n	30	60	
Age of onset, median (IQR)	54.5 (41.5, 59.5)	56.5 (41.5, 67.25)	0.296
QMG, median (IQR)	12.5 (10.25, 15.75)	12 (9.75, 16.25)	0.677
BMI, mean \pm sd	24.191 \pm 3.3908	25.622 \pm 4.3979	0.093
Duration, median (IQR)	8 (1.5, 26.25)	5 (2, 15)	0.221
RBC, median (IQR)	4.55 (4.1425, 4.975)	4.615 (4.33, 4.98)	0.376
Hb, median (IQR)	138 (127.25, 145.25)	144 (135.75, 155.25)	0.098
WBC, median (IQR)	6.35 (5.425, 9.05)	6 (4.85, 6.85)	0.145
LYM, median (IQR)	1.915 (1.5175, 2.5125)	1.7 (1.4, 2.13)	0.271
PH, median (IQR)	7.41 (7.3925, 7.43)	7.41 (7.39, 7.41)	0.346
PO2, median (IQR)	75.32 (69.5, 79.875)	75.64 (71, 79)	0.917
PCO2, median (IQR)	40.59 (38.25, 44.025)	40.59 (38.55, 42.4)	0.619
AChR-Ab, n (%)			0.393
<10	16 (17.8%)	32 (35.6%)	
>.20	7 (7.8%)	8 (8.9%)	
10~20	7 (7.8%)	20 (22.2%)	
Titin-Ab, n (%)			0.361
Positive	10 (11.1%)	26 (28.9%)	
Negative	20 (22.2%)	34 (37.8%)	
RNS, n (%)			1.000
Negative	5 (5.6%)	10 (11.1%)	
Positive	25 (27.8%)	50 (55.6%)	
Gender, n (%)			0.025
Female	19 (21.1%)	23 (25.6%)	
Male	11 (12.2%)	37 (41.1%)	
Hypertensionn, n (%)			0.213

No	22 (24.4%)	36 (40%)	
Yes	8 (8.9%)	24 (26.7%)	
Smoke, n (%)			0.742
No	22 (24.4%)	42 (46.7%)	
Yes	8 (8.9%)	18 (20%)	
Drink, n (%)			0.549
No	26 (28.9%)	49 (54.4%)	
Yes	4 (4.4%)	11 (12.2%)	
Extraocular, n (%)			0.119
Yes	22 (24.4%)	52 (57.8%)	
No	8 (8.9%)	8 (8.9%)	
Palpebralis, n (%)			0.067
Yes	18 (20%)	47 (52.2%)	
No	12 (13.3%)	13 (14.4%)	
Bulbar, n (%)			0.446
No	23 (25.6%)	50 (55.6%)	
Yes	7 (7.8%)	10 (11.1%)	
Vegetative, n (%)			0.607
No	24 (26.7%)	52 (57.8%)	
Yes	6 (6.7%)	8 (8.9%)	
Thymoma, n (%)			0.569
No	25 (27.8%)	54 (60%)	
Yes	5 (5.6%)	6 (6.7%)	
Thymic_hyperplasia, n (%)			0.025
No	28 (31.1%)	44 (48.9%)	
Yes	2 (2.2%)	16 (17.8%)	
MGFA, n (%)			0.292
IIA	11 (12.2%)	21 (23.3%)	
IIB	4 (4.4%)	12 (13.3%)	
IIIA	8 (8.9%)	10 (11.1%)	

III B	3 (3.3%)	14 (15.6%)
IV B	3 (3.3%)	3 (3.3%)
V	1 (1.1%)	0 (0%)
